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A bead-assisted flow cytometry 
method for the semi-quantitative 
analysis of Extracellular Vesicles
Henar Suárez1,2,5, Ana Gámez-Valero3,4, Raquel Reyes5,6, Soraya López-Martín1,2, María Josefa 
Rodríguez7, José L. Carrascosa7, Carlos Cabañas5, Francesc E. Borràs3,4,8 & María Yáñez-Mó  1,2,5
Most experimental approaches commonly employed for the characterization and quantitation of 
EVs are time consuming, require of specialized instrumentation and often are rather inaccurate. To 
circumvent the caveats imposed by EV small size, we used general and specific membrane markers in 
bead assisted flow cytometry, to provide a semi-quantitative measure of EV content in a given sample. 
EVs were isolated from in vitro cultured cells-conditioned medium and biological fluids by size exclusion 
chromatography and coupled to latex beads to allow their detection by standard flow cytometers. Our 
analyses demonstrate a linear correlation between EV concentration and Mean Fluorescence Intensity 
values in samples cleared of protein contaminants. Comparison with one of the most widespread 
method such as NTA, suggests a similar linear range and reliable accuracy to detect saturation. 
However, although detection of the different biomarkers is feasible when tested on ultracentrifugation-
enriched samples, protein contamination impairs quantitation of this type of samples by bead-based 
flow cytometry. Thus, we provide evidence that bead-assisted flow cytometry method is an accurate 
and reliable method for the semiquantitative bulk analysis of EVs, which could be easily implemented in 
most laboratories.
Extracellular vesicles (EVs) include a variety of vesicles released to the extracellular media by most cell types as 
intercellular communication vehicles. EVs may transfer bioactive lipids, proteins, mRNA, miRNA or non-coding 
RNA, between cells1, 2. The term EV incorporates exosomes, microvesicles and apoptotic bodies, which differ 
in their size and origin. Exosomes have an endocytic origin and their diameter range between 30 and 150 nm. 
Microvesicles, however, originate by direct budding from the plasma membrane and are between 100 nm and 
1 μm in diameter, while apoptotic bodies range from 1 μm to 5 μm and are released by dying cells2.
Besides their role in cell communication, EVs have recently emerged as a novel source of potential biomarkers 
for several diseases, since they can be easily obtained from body fluids such as urine3, 4, blood5, saliva or breast 
milk4 and their composition may be directly dependent on the physiological and/or pathological state of the 
patient. In addition, the number of EVs secreted can change upon the onset of different pathologies, so detecting 
variations in EV numbers could be of great relevance for diagnosis, especially in cancer patients6. Although there 
is a high heterogeneity in protein composition of EVs, yet, some proteins including tetraspanins, the Tumour 
susceptibility gene 101 (Tsg101), Major Histocompatibility Complex molecules (MHC) or abundant GPI-linked 
molecules have been classically considered as common abundantly present elements on the surface of these 
vesicles7–9.
Because of their small size and heterogeneity, detection and quantitation of EVs have become difficult tasks. 
Some techniques have emerged, including Nanoparticle tracking analysis (NTA), that are currently the most 
widely employed –i.e. “the gold standard”- for their characterization. Its main restriction lies in the discrimination 
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between vesicles and contaminating particles or protein aggregates present in the isolated sample, thus rendering 
inaccurate results in polydispersed samples.
To overcome some of these limitations, we propose a method allowing a semi-quantitative assessment of 
EVs in homogeneous and heterogeneous samples, reasonably unexpensive and easy to implement in any lab 
equipped with a standard flow cytometer. Our system is based on the detection of abundant EV proteins, such 
as tetraspanins, CD59 or MHC molecules by flow cytometry. To allow detection of EVs in conventional cytom-
eters, vesicles are coupled to 4 μm diameter aldehyde-sulfate latex beads10, 11. Bead-based flow cytometry, usu-
ally coupling the EV-marker antibody to the beads, has been previously employed for EV characterization12, 13. 
Here we report a modification of that system for semi-quantitative analyses of EV samples. We directly use 
aldehyde-sulfate beads, not to exert any restriction in the binding process14 so that the total population of vesi-
cles is included in the analysis. In this context, we demonstrate that linear changes in the MFI of several markers 
correlate with dilution of the samples thus allowing to build standard curves for the semi-quantitative evaluation 
of vesicles recovered from cell line cultures or biological fluids of interest. We provide evidence of the use of this 
method in EV isolated from tumor or primary cells as well as from human body fluids such as urine.
Material and Methods
Antibodies. Anti–HLA-A,B (clone W6/32;15), anti-CD59 (clone VJ1/ 12;16), anti-CD9 (clone VJ1/20) and 
anti-CD63 (clone TEA3/10), previously described17 and anti-CD81 (clone 5A6), kindly provided by S. Levy 
(Stanford University, CA), were used for the detection of EV-markers.
Cells. SK-MEL103 human melanoma cell line was cultured in DMEM (GE Healthcare) supplemented with 
10% Fetal bovine serum (FBS; GE Healthcare). Conditioned medium for EV isolation was collected twice a week. 
Primary T-lymphoblasts were isolated from human peripheral blood using a Ficoll (Biochrom) density gradient 
centrifugation as described elsewhere18. After activation with phytohaemagglutinin (PHA; Sigma) (1 µg/ml) for 
24 h, 3 × 106 cells/ml were cultured in RPMI (GE Healthcare) supplemented with 10% FBS and interleukin- 2 
(IL2) (50 U/ml). Cells were diluted every two days to 3 × 106 cells/ml in IL-2 containing media, and conditioned 
media was collected after one week of culture. FBS was depleted of bovine EVs by ultracentrifugation at 100,000xg 
for 16 h (Sorvall AH- 627 rotor, L8–70M ultracentrifuge, Beckman).
EV isolation by size exclusion chromatography (SEC). Conditioned media or urine was recovered 
and centrifuged at 400 g for 5 minutes and at 2,000 g for 10 minutes to remove cells and cell debris. The cleared 
supernatant (45 mL) was concentrated by ultrafiltration at 2,000 g for 30 min using Amicon Ultra-15 Centrifugal 
Filter Units (Millipore, Billerica MA). This last step was repeated until the whole supernatant was concentrated 
to a final volume of 1.5 ml which was loaded onto a SEC column for EVs purification as previously described19. 
Briefly, Sepharose CL-2B (Sigma Aldrich) was stacked in a 20 ml syringe (BD, Plastipak), reaching a final matrix 
length of 4.3 cm and 2 cm in diameter and equilibrated with PBS. For EVs it has been reported that this set-
ting will collect together particles larger than 70 nm19. Elution was performed by gravity with PBS, collecting 20 
sequential fractions of 500 µl. Soluble protein elution was confirmed to be in the last fractions (15–20) using BCA 
assay. Detection of those fractions enriched in EVs was performed by bead-based flow cytometry analysis of each 
individual fraction using anti-CD63 antibody (Fig. 1). Only the three fractions with highest MFI values for this 
EV marker (commonly 8th–10th) were pooled for further EV downstream analyses.
EV enrichment by Ultracentrifugation. Cell culture supernatants were recovered and centrifuged at 
400 g for 5 minutes and at 2,000 g for 10 minutes to remove cells and cell debris. Supernatants were centrifuged 
again at 17,000 g for 20 minutes and then at 100,000 g for 2 h (Sorvall AH- 627 rotor, L8-70M ultracentrifuge, 
Beckman). The 100,000 g pellet was then washed with PBS (30 ml) and centrifuged again for 2 h at 100,000 g. EVs 
were resuspended in 1.5 ml of PBS.
Flow cytometry assays. 50 μl of each fraction isolated by SEC (diluted or not) or by ultracentrifugation 
were incubated with 0.25 μl of aldehyde/sulfate-latex beads (ø = 4 μm; 5.5 × 106 particles/ml; Invitrogen, Carlsbad, 
CA) for 15 min at RT. Dilutions of the EV samples were performed with the same buffer used for their elution 
(PBS). Bead concentration was chosen to be large enough to be easily detected by the flow cytometer having 
enough events for proper statistics (over 5000), and small enough to use a small volume of sample. Then 1 ml 
of BCB (PBS supplemented with 0.1% BSA; Roche, and 0.01% NaN3; G-Biosciences) was added and the sam-
ple incubated overnight on rotation. Bead-coupled EVs were pelleted by centrifugation at 2,000 g for 10 min-
utes, washed with 1 ml of BCB and centrifuged again. The pellet was resuspended with 50 μl of BCB per analysis 
and stained using hybridoma supernatant of anti-MHC-I (W6/32), anti-CD59 (VJ1/12), anti-CD9 (VJ1/20), 
anti-CD63 (TEA3/10), anti-CD81(5A6) as primary antibodies and FITC-conjugated secondary antibodies 
(ThermoFisher Scientific) for 30 minutes at 4 °C. Negative control was obtained by incubating the beads cou-
pled with the undiluted EV sample, with an isotype control followed by secondary antibody, or in the absence 
of primary mAb. Washing steps were performed once after primary and twice after secondary Ab labelling with 
150 μl of BCB and centrifugation at 2,000 g for 10 minutes. Data was acquired in conventional flow cytometers 
(FacsVerse and FACSCanto A, BD Biosciences, San Jose, CA) and analysed with the FlowJo software (version Tree 
Star, Ashland, OR). Gating of EV-decorated 4 μm in diameter beads was performed based on FCS/SSC parame-
ters, so that unbound EVs or possible antibody aggregates are excluded from the analysis.
Protein concentration measurement. Pierce BCA Protein assay kit was used following manufacturer 
instructions. Detection provided by manufacturer, ranges between 5–2000 µg/ml.
www.nature.com/scientificreports/
3SCIENTIFIC RepoRts | 7: 11271  | DOI:10.1038/s41598-017-11249-2
Nanoparticle tracking analysis. Size distribution and concentration of EVs was determined using 
NANOSIGHT LM10 (Malvern Instruments Ltd, Malvern, UK) equipped with charge-coupled device (CCD) 
camera (model F-033) and a 638 nm laser. Analysis was performed using the NTA 3.0 software. Detection thresh-
old was set to 5, and blur and Max Jump Distance were set automatically. Diluted (100- to 1200-fold) fractions 
were loaded in the NTA device and 60 s videos were recorded in triplicate with the camera shutter at 30.02 ms and 
the camera gain at 650, as recommended by the manufacturer.
Sample processing for Transmission Electron Microscopy (TEM). For ultrastructural studies, 
a latex beads pellet was treated with a mixture of 2% formaldehyde (Ultra Pure EM Grade, Polysciences Inc., 
Philadelphia, USA) and 2.5% glutaraldehyde (EM Grade, TAAB Laboratories Equipment Ltd., Berks, UK) in PBS 
for 1 h at room temperature. The pellet was then washed with PBS and distilled water, post-fixed for 45 minutes 
with 1% osmium tetroxide (TAAB Laboratories Equipment Ltd.) in PBS, washed with distilled water, treated 
during 45 minutes with 1% aqueous uranyl acetate (Electron Microscopy Sciences, Hatfield, USA), washed again 
and dehydrated with growing quantities (30%, 50%, 70%, 90% and 100%) of ethanol seccosolv (Merck KGaA, 
Darmstadt, Germany) at room temperature. The sample was maintained in an eppendorf throughout the process 
and finally embedded in epoxy resin 812 (TAAB Laboratories Equipment Ltd.) contained in beem embedding 
capsule (TAAB, polythene truncated pyramid 5, 2 mm diameter). The epoxy resin was polymerized for 2 days 
at 60 °C after a 5 minutes-centrifugation step at 14500 rpm. Due to the properties of the latex beads, the sample 
remained in the opposite side of the truncated pyramid of the beem capsule. Ultrathin, 70-nm-thick sections were 
obtained from that side with an Ultracut UCT ultramicrotome (Leica Microsystems), transferred to buttonhole 
Nickel EM grids (GS2 × 1-N3, Gilder, Lincolnshire, UK) and stained with 3% aqueous uranyl acetate (10 minutes) 
and lead citrate (2 minutes) (Electron Microscopy Science). Sections were visualized on a JEOL JEM 1200 EXII 
electron microscope operating at 100 kV (JEOL Ltd., Tokyo, Japan).
Statistical analysis. Statistical analyses and linear regressions were calculated with GraphPad Prism 
(GraphPad Software Inc).
Figure 1. SEC-elution profile of EV samples. Conditioned media from melanoma cells (A) and T-lymphoblasts 
(B) cultures were processed using size exclusion chromatography (SEC). The obtained fractions were analysed 
by flow cytometry using anti-CD63 antibody after coupling EVs with aldehyde-sulfate beads. Protein 
concentration was also measured by BCA assay for each fraction and plotted in the right y-axis. Fold changes 
of mean fluorescence intensity (MFI) relative to the isotype control are plotted in the left y-axis. (C) Beads 
incubated with EVs (left) or EVs in solution (right) were incubated with primary and fluorochrome-labelled 
secondary antibodies. The flow cytometer gate used to analyse the beads is depicted in the SSC/FCS dot-plot. 
(D) Those beads showing CD63 positive staining were analysed by transmission electron microscopy. Bar: 
100 nm.
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Ethics statement: Experimental protocols for human samples were carried out following international reg-
ulations, including written consent by the donors, and approved by the Ethical Committee of the Hospital 
Universitario de la Princesa.
Results
Bead-assisted flow cytometry can be used as a highly sensitive semi-quantitative method for 
EV analysis. EVs were isolated from culture supernatants of human primary T-lymphoblasts or SK-MEL103 
melanoma cells, using Size Exclusion Chromatography (SEC) to remove most protein contaminants from EV 
samples. All 20 fractions collected were analysed for protein content by BCA assay and characterized by bead-as-
sisted flow cytometry using antibodies against classical EV-marker CD63 (Fig. 1A,B). Bead-assisted flow cytom-
etry was performed by incubating the samples with 4 μm in diameter aldehyde/sulfate-latex beads. This size of 
the beads is such that they can be clearly detected and resolved from background signal by regular cytometers 
(Fig. 1C). No signal could be observed in the cytometric bead gate after incubating the EV samples with anti-
bodies (primary and secondary), suggesting that even antibody-induced aggregates cannot be resolved from 
background in this kind of equipment (Fig. 1C). Electron microscopy analyses of beads incubated with the CD63 
positive fractions demonstrated the presence of EV adsorbed on the surface of the beads (Fig. 1D). As previously 
described10, EVs detected as the CD63 positive fractions, were recovered before the elution of soluble proteins 
(Fig. 1A,B). Already from this initial analysis, it became apparent that the power of detection of bead-assisted 
flow cytometry is much higher than that of protein analyses such as the BCA assay (with detection range between 
5–2000 µg/ml), which for vesicular fractions lay close or even below its detection limit.
Given the high heterogeneity of EVs, we first assessed the most suitable markers for each EV sample, to be 
used in bead-assisted flow cytometry. The relative expression of EV markers in vesicles derived from two different 
cell cultures, SK-MEL103 melanoma cell line and primary human T-lymphoblasts, was assessed. The analysis 
included three different tetraspanins commonly employed as EV markers: CD9, CD81 and CD63. In addition, 
we assessed the expression levels of MHC-I molecules as well as the GPI-linked complement regulatory molecule 
CD59, which is highly expressed in most cell types20 (Fig. 2). Despite being these markers conserved in samples 
from different origins, expression levels can differ on the plasma membrane of the producing cells as well as on 
EVs. In our case, these differences were remarkable for CD81, CD9 and MHC class I (Fig. 2). This preliminary 
profiling has to be performed in order to select the appropriate combination of markers to measure the EVs pro-
duced by a given cell line or present in a specific biological fluid.
To assess whether the output of our bead-assisted flow cytometry method is in linear relation with EV con-
centration, we performed a set of EVs dilutions using melanoma EVs. Each individual EV dilution was coupled 
to the beads, incubated with the different antibodies and finally analysed by flow cytometry (Fig. 3). In the same 
samples, the protein content of each dilution was determined. As shown in Fig. 3, protein measurements exhibit 
a linear correlation in all the samples analysed, yet at higher EV dilutions (i.e. at lower dilution factor values) the 
values were close to the detection limit. In contrast, the MFI values for CD63 and CD59 detection still showed a 
linear response with these very diluted samples, while reflected saturation in less diluted samples (Fig. 3). In these 
particular melanoma vesicles, the expression levels of tetraspanins CD81 and CD9 as well as of MHC-I are lim-
ited, so that their changes in MFI values are small throughout the range of sample dilutions. These data strongly 
suggest that a high MFI is crucial for a good dynamic range and sensitivity of the quantitation method, as is the 
case for anti-CD63 and anti-CD59 in melanoma-derived EVs. In the case of T-lymphoblast-derived EVs, both 
CD63 and MHC-I were selected among those showing higher MFI to be used in the subsequent analyses.
To estimate the range of linear detection as well as the detection limit of our measurement, we increased the 
range of dilutions of SEC-isolated EV samples analysed (Fig. 4). As for previous experiment, serial dilutions were 
coupled to beads and stained with anti-CD63 and anti-CD59 for melanoma-EVs or anti-CD63 and anti-MHC-I 
for T-lymphoblasts-EVs. MFI values were normalised relative to the negative control (isotype Ab-stained beads), 
Figure 2. Characterization of EVs. T-lymphoblasts and melanoma EVs, isolated by SEC, were analysed by 
bead-based flow cytometry using antibodies against common EV markers. Antibodies used were anti-CD59 
VJ1/12, anti-CD63 TEA3/10, anti-CD81 5A6, anti-CD9 VJ1/20, and anti-MHC-I W6/32 mAbs. Data 
correspond to the mean ± SEM of the MFI fold change referred to the negative control, in 3–5 independent 
experiments.
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and plotted against the dilution factor. A typical curve showing a saturated phase was observed when plotting the 
MFI fold-increase against the EV sample dilution (Fig. 4A,C). The protein content of the undiluted samples was 
determined by BCA to be 116.85 µg/ml in the case of T-lymphoblasts-EVs and 148.16 µg/ml for melanoma-EVs. 
We used these values to convert the linear range of the plot to MFI versus protein content (Fig. 4B,D). These 
analyses revealed a good linear behaviour, with very high r2 values and p values < 0.001, in the range between 
1 to 15 ng for melanoma-EVs using anti-CD63 and anti-CD59. In the case of T-lymphoblasts-EVs, there was a 
good linear response in the range between 30 and 150 ng for MHCI and CD63 labelling. The limit of detection 
of the measure, usually determined as the background signal +3 times the standard deviation of the background 
signal, has been plotted in the figure, to determine the limit of EV detection in our assay. As shown in Fig. 4B,D, 
the limit of EV detection depends on the antibody used for staining, since it corresponds to the crossing point 
of the regression curve with the detection limit of the measure, but in all cases lay in the range of ng of vesicular 
proteins. The detection limit for MHCI in T-lymphoblast is really low, suggesting that we can indeed detect very 
few EVs with this marker. Larger dilutions should be analysed to have an accurate regression curve in this very 
diluted sample range, in order to obtain the exact limit of detection with this marker.
Comparison of bead-assisted flow cytometry with Nanoparticle Tracking Analysis. We next per-
formed parallel analyses of different sample dilutions by the current “gold-standard” method in EV quantitation, 
NTA, and bead-assisted flow cytometry. As it can be seen in Fig. 5, the linearity of NTA measurements was clearly 
maintained for melanoma EV samples diluted from 10 to 200 times, that corresponded to 25–0.9 × 109 vesicles, 
respectively. However, at higher concentrations (0.20 dilution factor), the result provided by NTA was smaller 
than the 10-times dilution, with no clear indication of saturating conditions. In comparison, the linear range 
of bead-assisted flow cytometer was narrower (in this case ranging from 50 to 200-times dilution (0.02–0.005 
dilution factor), as depicted in Fig. 5). However, saturation of the measure occurred always at the same values of 
MFI for each marker (~15 folds the MFI value of the negative control for anti-CD63, ~8 folds for anti-CD59). If 
we calculate the number of EVs detected by the flow cytometry method, based on NTA absolute numbers, our 
detection range corresponds to 5 × 102 to 3.5 × 103 EVs/bead, suggesting that saturation of the flow cytometry 
signal occurs at the point were no more vesicles can be bound to beads, so the signal is maximum. This saturation 
point is therefore constant for each marker and sample type since when beads are completely covered by vesicles, 
the signal cannot increase anymore, independently on the antibody used for staining. In addition, sensitivity of 
this method, taken as the change in signal with changes in concentration, is higher than for NTA, since in the 
detection range, the slopes of the regression curves are very pronounced, suggesting that small changes in EV 
content are reflected in big changes in MFI.
Thus, for an unknown sample, our method enables its semi-quantitative analysis by measuring the fluores-
cence signal of the sample, while the parameters of the standard curve will give the operator information on the 
suited range of detection, based on the maximum MFI values reached for a given marker.
Figure 3. Analysis of antibody-staining detection of EV surface molecules in flow cytometry assays. Pooled 
SEC fractions containing melanoma EVs were sequentially diluted. Every dilution was analysed using a panel 
of antibodies: anti-CD63 (TEA3/10) in red, anti-CD59 (VJ1/12) in green, anti-CD81 (5A6) in yellow, anti-CD9 
(VJ1/20) in purple and anti-MHCI (W6/32) in blue. The ratio of the MFI obtained relative to the negative 
control is plotted in the left y-axis. Protein content is plotted in the right y-axis and dotted line. The dilution 
factor of each measure is plotted on the x-axis (n.d.: non-diluted).
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Bead-assisted flow cytometry can be employed in biofluid-derived samples. Since exosomes are 
becoming important biomarkers for many pathologies, we were interested in testing if this relation between MFI 
and EVs number/concentration, could be also applied to biological fluids. EVs from human urine where isolated 
and purified by SEC, and thereafter submitted to sequential dilutions to be measured by flow cytometry using 
antibodies against tetraspanins CD63 and CD9 (Fig. 6). As shown in the plot, EVs from human fluids also main-
tain a strong linearity between the amount of total protein and MFI values, as reflected by the good correlation 
parameters for both markers.
The use of bead-assisted flow cytometry in protein-containing samples. SEC has the clear advan-
tage of greatly reducing protein contaminants in EV samples. However, the majority of the research in the EV 
field is still using serial ultracentrifugation to enrich EVs from cell culture supernatant or biofluids. To assess 
whether the presence of protein contaminants could interfere with our bead-assisted flow cytometry assay, we 
coupled SEC-isolated EVs with beads in the presence of increasing amounts of “contaminant protein”. To mimic 
as much as possible the composition of the original fluid, this “contaminant protein” was obtained from the 
protein-containing fractions after SEC purification of the same samples (fractions from 18 to 20). As observed in 
Fig. 7A, the presence of a small amount of protein (around 1 µg/ml) during the coupling process did not impair 
the detection of the EV marker by flow cytometry. A good signal could still be observed with protein contamina-
tion as high as 7 µg/ml, but the MFI values decreased thereafter.
Figure 4. MFI values linearly correlate with EV content. EVs fractions were subjected to serial dilutions. 
Diluted EVs were coupled to beads and analysed by flow cytometry. Graphs on the top correspond to the data 
for melanoma-derived EVs and those on the bottom to data for T-lymphoblast-EVs. (A) and (C) EV dilution is 
plotted on the x-axis and fold change of MFI relative to negative control on the y-axis. Inset in A corresponds 
to the highest dilutions of the same graph. (B) and (D) Protein content of the undiluted fraction was measured 
using a BCA assay to represent MFI fold change (error bars correspond to SD values) versus protein content in 
the linear range (dilutions 1/100-1/1000 for melanoma-EVs and 1/8-1/40 for the T-lymphoblast-EV sample). 
Antibodies used were anti-CD63 TEA3/10 mAb, anti-CD59 VJ1/12 mAb and anti-MHC-I W6/32 mAb. 
The limit of detection of the measure, calculated as the background signal plus 3 times its SD, is shown as a 
horizontal dashed line. The detection limit with each marker is depicted with the corresponding colour as a 
vertical dashed line. The values for r2 are depicted in the graphs. In all cases p < 0.0001.
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The presence of some protein in the coupling buffer seems to favour the coupling of EVs to the heavily charged 
beads or, in addition, could prevent the adherence of EVs to the plastic tube, thus we next performed the coupling 
either in glass or plastic tubes and in the absence of protein or in our standard conditions (0.1% BSA (BCB)). 
These specific experiments were performed using highly concentrated samples, in the saturation phase of the 
curve, in which differences in MFI should only be due to effects on the coupling efficiency. As shown in Fig. 7B, 
in the presence of 0.1% BSA the coupling efficiency was equal for all samples. In the absence of BSA, however, a 
drastic decrease in MFI could be observed in the 10-times dilution when using plastic tubes. Thus, the presence 
of a small amount of protein either improves or does not affect detection of EVs, being this positive effect more 
Figure 5. Comparison of flow cytometry-based and NTA quantitative analyses. A set of serial dilutions of 
melanoma-derived EVs were analysed NTA (particle concentration plotted on the left y-axis) and by bead-
based assay (MFI folds of negative control plotted on the right y-axis as measured with anti-CD63 (TEA3/10) 
and anti-CD59 (VJ1/12) mAbs). The linear range of the fold change is also represented in the graph.
Figure 6. MFI values obtained in human urine samples also correlate with dilution factor and protein 
concentration. EVs isolated from urine by SEC, were submitted to sequential dilutions and analysed by flow 
cytometry using two antibodies: anti-CD63 (TEA3/10) in black and anti-CD9 (VJ1/20) in brown. Protein 
content of the undiluted SEC sample was measured by BCA assay. SD values and the values for r2 are depicted in 
the graphs. In all cases p <0.0001.
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evident in samples with scarcer EVs. In addition, these results suggest that some plastic tubes may be highly adhe-
sive for EVs avoiding their coupling to the beads.
Finally, to assess the suitability of bead-assisted flow cytometry in ultracentrifuged samples, we performed 
similar analyses with melanoma EV samples enriched by ultracentrifugation (UC). Serial dilutions of the 
UC-pellet were performed before coupling to the beads. In sharp contrast to the previous results, in this case 
vesicular markers could be detected at very low signal intensity in most samples, and the linearity with concen-
tration could not be observed (Fig. 7C).
Discussion
Extracellular vesicle isolation and accurate quantification still remain as one of the main challenges in this field 
of research. The diverse isolation procedures described render samples with different levels of contaminants 
that may turn out to yield very disparate results. Lately, serial ultracentrifugation, the most commonly used 
EV-isolation method, is being questioned because of its lack of specificity, since it does not allow establishing 
a strict restriction over the presence of soluble proteins or aggregates. In this situation, SEC has emerged as an 
alternative advantageous method that overcomes many of the limitations of ultracentrifugation21, providing sam-
ples with high levels of intact vesicles and with reduced protein contamination by just appropriate selection of the 
pore size of the matrix.
Protein quantification has been commonly used as a fast method to determine the amount of vesicles present 
in a sample. However, these results have to be considered carefully; a direct correlation between the protein con-
tent and the number of vesicles in a given sample cannot be directly established, not only because of the highly 
heterogeneous nature of EVs, both in their size and composition, but mostly because of the high variability in 
the relative amount of accompanying protein contaminants co-enriched in the different isolation methods. These 
protein contaminants will cause an overestimation in the number of vesicles based not only on protein quantita-
tion, but also on NTA analyses, since this latter technique cannot properly discriminate between EVs and large 
protein or contaminant aggregates. While SEC-based isolation may not produce completely pure EV samples22, 
Figure 7. MFI determination is impaired by high levels of protein contamination. (A) EVs isolated by SEC 
from melanoma conditioned medium, were coupled to the beads in the presence of increasing amounts of 
protein from the last fractions of the SEC chromatography and analysed by flow cytometry using anti-CD63 
(TEA3/10) antibody. Data correspond to the mean ± SEM of the MFI referred to that of the negative control, 
in three independent experiments. (B) Protein contamination greatly impairs the coupling to the beads, 
especially when performed in plastic tubes. Data correspond to the mean ± SEM of the MFI referred to 
that of the negative control, in three independent experiments. (C) Melanoma-EVs were concentrated by 
ultracentrifugation and subjected to serial dilutions before coupling to beads to be analysed by flow cytometry 
after staining with either anti-CD63 (TEA3/10) and anti-CD59 (VJ1/12) mAbs.
www.nature.com/scientificreports/
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it has the advantage of highly reducing protein contamination, thus permitting a more accurate and comparable 
quantitation of EVs.
The development of a reliable method to quantify EVs using flow cytometry requires using antibodies with 
a high sensitivity and a good linear response. Linearity involves a strong correlation between EV concentration 
and fluorescence signal. Mean Fluorescence Intensity (MFI) values depend on both the sample properties as well 
as on the combination of antibodies (primary/secondary) used for detection. As EVs size is under the resolution 
limit of any conventional cytometer, their coupling to latex beads becomes essential for their analysis using this 
system12, 13. There are now several commercially available kits of beads coupled to antibodies specific for EV 
markers, being CD63 the most widely used23. However, because of the high heterogeneity of these vesicles, it is 
especially important to ensure that there is no preference for any subpopulation of vesicles for their quantitative 
assessment. In this respect, we should remark that the proposed method is based on the bulk detection of EVs. 
Since a given bead will accommodate several EVs potentially expressing different sets of markers, in the end, each 
fluorescent dot detected in the flow cytometer suppose a combination of vesicles among which there are some 
with the molecule recognized by the specific antibody employed for quantitation. When the sample is diluted, 
the number of vesicles covering each bead will be smaller and thus the signal intensity. However, in contrast with 
other bulk methods, flow cytometry enables the detection of small amounts of particles, because it accumulates 
the signal of several EVs binding to a bead, also enabling amplification by primary-secondary antibodies. It also 
has a very good linear response and high sensitivity so it can detect changes in concentration precisely. These 
advantages make the proposed flow cytometry-based method a superior alternative for the accurate EVs quanti-
tation compared to most commonly used methods.
This quantification method depends on the specific pattern of expression of surface molecules found in the 
EVs of a given cell type. Therefore, a previous characterization of the EV profile of interest using the same experi-
mental approach is needed. Here we have combined classical EV markers, such as tetraspanins, with other highly 
abundant membrane proteins, such as the GPI-linked regulatory protein of the complement cascade CD59, which 
is highly expressed in many cell types. For T-lymphoblasts, MHC-I has also proven to be a very abundant EV 
marker. Quantitative analysis should be rather performed using those markers with the highest expression levels, 
so that concentration changes are precisely reflected in changes in MFI and sensitivity of the method is increased. 
Dim fluorescence intensities involve small signal-to-noise ratios, which prevent the detection of relatively small 
variations in MFI values. In any case, because not only changes in vesicle number, but also in composition may 
occur, the ideal scenario will include the parallel assessment of a set of markers for each sample. If EV properties 
remain unaltered among different samples, quantitation of an unknown sample is very consistent even using dif-
ferent standard curves based on different markers. This implies that changes in EV composition will be also easily 
detected if within a panel of given markers there is a discrepancy in the behaviour of any of them.
It is known, that a single cell can produce vesicles with different protein content. Some emerging techniques 
such as immunoaffinity isolation of EVs, may be able to discriminate among different EV subpopulations, but 
detection limits could be poorer. Moreover, by isolating EV based on single expression marker, all the charac-
terization of those EVs will be skewed from the beginning, being exclusively restricted to those EVs that can be 
bound to the antibody linked to the beads. On the contrary, aldehyde-sulfate latex beads are densely covered 
with high affinity binding groups. The combination of unbiased high affinity binding to the beads, with specific 
and bright antibody detection, rendered a capacity of detection in the range of ng of protein. Conversion of these 
results to vesicle numbers (based on NTA analyses) suggests that we could detect 3–12 × 107 vesicles, correspond-
ing to a range from 5 × 102 to 3.5 × 103 EVs/bead in the experimental conditions used. These numbers suggest 
that the upper limit is governed by steric hindrance, so that possibly it could be overcome by using larger beads, 
as increasing the surface available for vesicle binding would result in higher concentration of vesicles needed to 
reach the saturation phase of the signal. This should be critical to expand the linear range of detection.
When compared on the same samples to the current “gold standard” in the field (NTA), the bead-based assay 
showed high accuracy at the lower limit range. NTA is able to give accurate results at lower concentration of 
vesicles (up to around 3.0 × 1010). However, at high concentrations linearity is lost. MFI absolute numbers, in 
contrast, provide a clear indication of saturation of the measure. In addition, the volume of sample required is 
much less than for NTA, and acquisition time is shorter. Moreover, NTA cannot discriminate the nature of the 
particles analysed, thus being unable to distinguish EVs from protein aggregates. Since our method is based on 
the detection of membrane-bound markers, this drawback is also resolved.
To improve the inter-laboratory robustness of our method, we have analysed some parameters that could 
affect the outcome of the measurement. In this sense, we have observed that a small amount of protein (0.1% 
BSA was our routine incubation condition) improves detection. Importantly, performing the coupling in the 
presence of protein greatly reduced the adherence of EVs to some plastic tubes. Glass vials or low-protein binding 
plastic tubes are better suited for the coupling of EVs to beads, since they do not compete with latex beads for EV 
binding.
Finally, although the same methodology could also be used to characterise the composition of EV samples 
enriched by ultracentrifugation, our results showed that the linear response related to concentration observed 
with SEC samples is lost with UC samples. This effect could be probably explained by the excess of contaminant 
proteins in UC samples that affect coupling of EVs to the beads, thus rendering lower MFI values that ultimately 
hampered linearity.
In summary, here we report a simple and feasible bead-based method for the semi-quantitative character-
ization of EVs from homogeneous and heterogeneous samples with low protein contamination. This method 
could be easily adapted to most laboratories with access to basic flow cytometers, thus allowing inter-laboratory 
comparison and standardization of their results.
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